+

NO20072235L - HCV-hemmende bicykliske pyrimidiner - Google Patents

HCV-hemmende bicykliske pyrimidiner

Info

Publication number
NO20072235L
NO20072235L NO20072235A NO20072235A NO20072235L NO 20072235 L NO20072235 L NO 20072235L NO 20072235 A NO20072235 A NO 20072235A NO 20072235 A NO20072235 A NO 20072235A NO 20072235 L NO20072235 L NO 20072235L
Authority
NO
Norway
Prior art keywords
present
hcv
bicyclic pyrimidines
relates
pyrimidines
Prior art date
Application number
NO20072235A
Other languages
English (en)
Norwegian (no)
Inventor
Dominique Louis Nest Surleraux
Pierre Jean-Marie Raboisson
Kenneth Alan Simmen
Tse-I Lin
Oliver Lenz
Original Assignee
Tibotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35448001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072235(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotech Pharmaceuticals Ltd filed Critical Tibotech Pharmaceuticals Ltd
Publication of NO20072235L publication Critical patent/NO20072235L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20072235A 2004-09-30 2007-04-30 HCV-hemmende bicykliske pyrimidiner NO20072235L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04104815 2004-09-30
EP05102810 2005-04-08
PCT/EP2005/054912 WO2006035061A1 (fr) 2004-09-30 2005-09-29 Pyrimidines bicycliques inhibant le vhc

Publications (1)

Publication Number Publication Date
NO20072235L true NO20072235L (no) 2007-06-28

Family

ID=35448001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072235A NO20072235L (no) 2004-09-30 2007-04-30 HCV-hemmende bicykliske pyrimidiner

Country Status (15)

Country Link
US (1) US7977342B2 (fr)
EP (1) EP1799218A1 (fr)
JP (1) JP5046942B2 (fr)
KR (1) KR20070058602A (fr)
CN (1) CN100594903C (fr)
AP (1) AP2007003923A0 (fr)
AR (1) AR052771A1 (fr)
AU (1) AU2005288858B2 (fr)
BR (1) BRPI0516751A (fr)
CA (1) CA2577745C (fr)
IL (1) IL181226A (fr)
NO (1) NO20072235L (fr)
RU (1) RU2380101C2 (fr)
TW (1) TW200626157A (fr)
WO (1) WO2006035061A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557112B2 (en) * 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
WO2006073610A2 (fr) * 2004-11-23 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux composes bicycliques heterocycliques, leur procede de preparation et compositions les contenant
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DK1869037T3 (da) * 2005-03-25 2011-10-24 Tibotec Pharm Ltd Heterobicykliske inhibitorer af HVC
CA2606760C (fr) 2005-05-04 2014-12-23 Renovis, Inc. Composes de tetrahydronaphthyridine et de tetrahydropyrido[4,3-d]pyrimidine et compositions de ceux-ci utiles dans lediraitement des conditions associees aux troubles et dysfonctions neurologiques et inflammatoires
AR056347A1 (es) * 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
WO2007011759A2 (fr) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibiteurs de la kinesine mitotique
EP1971611B1 (fr) 2005-12-21 2012-10-10 Abbott Laboratories Composes anti-viraux
CN101443334A (zh) * 2005-12-21 2009-05-27 艾博特公司 抗病毒化合物
US7763731B2 (en) 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
WO2007076034A2 (fr) 2005-12-21 2007-07-05 Abbott Laboratories Composes antiviraux
DE102006029074A1 (de) 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
WO2008021456A2 (fr) * 2006-08-16 2008-02-21 Cytovia, Inc. N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose, et leurs utilisations
CA2672737A1 (fr) 2006-12-20 2008-11-06 Abbott Laboratories Composes antiviraux
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2134716A1 (fr) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Inhibiteurs de pyrrolotriazine kinase
CN101981037B (zh) * 2008-01-30 2013-09-04 吉宁特有限公司 吡唑并嘧啶pi3k抑制剂化合物及使用方法
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010011620A1 (fr) * 2008-07-21 2010-01-28 Wyeth Composés 4-phénoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine et n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidine-4-amine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses
RU2473549C2 (ru) 2008-07-31 2013-01-27 Дженентек, Инк. Пиримидиновые соединения, композиции и способы применения
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
ES2392488T3 (es) 2008-11-20 2012-12-11 Genentech, Inc. Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP5572715B2 (ja) 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｎ−７置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
KR101469334B1 (ko) 2009-11-12 2014-12-04 에프. 호프만-라 로슈 아게 Ｎ-9-치환된 퓨린 화합물, 조성물 및 사용 방법
PL2552930T3 (pl) 2010-03-31 2016-02-29 Gilead Pharmasset Llc Krystaliczny 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1-(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian (S)-izopropylu
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
KR101991298B1 (ko) 2011-09-16 2019-06-21 길리애드 파마셋 엘엘씨 Hcv 치료 방법
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013164061A1 (fr) 2012-05-04 2013-11-07 dedeMERCK PATENT GMBH Dérivés de pyrrolotriazinone
RU2015111206A (ru) 2012-08-30 2016-10-20 Ниппон Синяку Ко., Лтд. Пиридиновое производное и лекарственное средство
AU2013314244A1 (en) * 2012-09-17 2015-03-12 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10A
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP6307524B2 (ja) * 2013-02-04 2018-04-04 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｐｄｅ４阻害薬としての、４−アミノ置換縮合ピリミジン化合物
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
LT3089971T (lt) 2014-01-01 2020-10-12 Medivation Technologies Llc Junginiai ir panaudojimo būdai
WO2016067099A1 (fr) 2014-10-29 2016-05-06 King Abdullah University Of Science And Technology Composé de 3-alkyle pyridinium à partir d'éponge marine rouge avec une activité antivirale puissante
CN107108610B (zh) * 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
US20180250303A1 (en) * 2015-08-25 2018-09-06 Bristol-Myers Squibb Company Tgf beta receptor antagonists
ES2969565T3 (es) 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
AU2017240076A1 (en) * 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JP6742452B2 (ja) * 2016-06-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｂｖ感染の処置および予防のための新規のテトラヒドロピリドピリミジン
US12319686B2 (en) 2019-01-17 2025-06-03 Hoffmann-La Roche Inc. Process for the preparation of tetrahydropyridopyrimidines
CN111825674A (zh) * 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
RU2746423C2 (ru) * 2019-09-02 2021-04-13 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)
CN111548349A (zh) * 2020-05-13 2020-08-18 厦门云凡医药科技有限公司 一种ret激酶抑制剂中间体及其制备方法
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
RU2123328C1 (ru) * 1996-04-19 1998-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Липосомальное противовирусное лекарственное средство для перорального применения
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1242385B1 (fr) 1999-12-28 2009-11-25 Pharmacopeia, Inc. Inhibiteurs de la cytokine, en particulier de tnf-alpha
AU2001294558A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1370553T3 (da) 2001-03-23 2006-09-11 Bayer Corp Rho-kinase-inhibitorer
EP1485376B1 (fr) 2002-03-15 2007-06-27 Vertex Pharmaceuticals Incorporated Compositions s'utilisant comme inhibiteurs de proteine kinases
EP1485380B1 (fr) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines inhibitrices des proteines kinases
WO2003077921A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles utilises comme inhibiteurs de proteine kinases
WO2003078426A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
AU2003291149A1 (en) 2002-11-22 2004-06-18 Scios, Inc. USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
US20040127575A1 (en) 2002-11-22 2004-07-01 Feng Ying Method for counteracting a pathologic change in the beta-adrenergic pathway
WO2004065392A1 (fr) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Pyridines et pyrimidines condensees et leur utilisation en tant que ligands du recepteur alk-5
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2004087056A2 (fr) * 2003-03-28 2004-10-14 Scios Inc. Inhibiteurs bi-cycliques a base de pyrimidine de tgf$g(b)
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
DK1869037T3 (da) 2005-03-25 2011-10-24 Tibotec Pharm Ltd Heterobicykliske inhibitorer af HVC
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas

Also Published As

Publication number Publication date
CN101031304A (zh) 2007-09-05
BRPI0516751A (pt) 2008-09-16
CA2577745A1 (fr) 2006-04-06
JP5046942B2 (ja) 2012-10-10
US7977342B2 (en) 2011-07-12
AR052771A1 (es) 2007-04-04
RU2007116176A (ru) 2008-11-10
IL181226A0 (en) 2007-07-04
AU2005288858A1 (en) 2006-04-06
CA2577745C (fr) 2012-11-27
AU2005288858B2 (en) 2011-04-21
AP2007003923A0 (en) 2007-02-28
IL181226A (en) 2015-03-31
KR20070058602A (ko) 2007-06-08
CN100594903C (zh) 2010-03-24
TW200626157A (en) 2006-08-01
WO2006035061A1 (fr) 2006-04-06
EP1799218A1 (fr) 2007-06-27
US20070155716A1 (en) 2007-07-05
RU2380101C2 (ru) 2010-01-27
JP2008514678A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
NO20072235L (no) HCV-hemmende bicykliske pyrimidiner
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
TW200716631A (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
NO20080540L (no) HCV-inhibitorer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
NO20064584L (no) Tetrahydropyridoindolderivater
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
NO20080879L (no) HCV-NS3-proteaseinhibitorer
EA200901241A1 (ru) Соединения для лечения гепатита с
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
WO2008057208A3 (fr) Inhibiteurs de protéase ns3 du vhc
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
SG163517A1 (en) Antiviral compounds and methods
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20073105L (no) Pyridazinonforbindelser
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
NO20073765L (no) Forbindelser for behandling av flaviviridae

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载